GlassScriptPhysician profile
Ravi K Saripalli
NPI 1235372244
$1,458.64
in general payments reported to CMS, 2019-2025
27 companies · $33.94 in 2025
The $33.94 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $13.83 · 2022: $412 · 2023: $553 · 2024: $312 · 2025: $33.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $253.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.43 | 2020-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $162.02 | 2022-2024 | Verquvo, Belsomra, Lagevrio |
| Amgen INC. | $129.43 | 2022-2024 | Evenity, Prolia |
| Dexcom, INC. | $111.09 | 2022-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $94.48 | 2022-2025 | Bexsero, Arexvy, Pediarix |
| Lundbeck LLC | $71.36 | 2023-2024 | Rexulti |
| Sobi, INC | $42.09 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $37.36 | 2023-2024 | Linzess |
| Biohaven Pharmaceutical Holding Company LTD. | $29.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.92 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.86 | 2019 | |
| Genzyme Corporation | $23.02 | 2024 | |
| Sanofi Pasteur INC. | $22.12 | 2019 | |
| Philips North America LLC | $20.36 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.75 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $19.66 | 2024 | Rexulti |
| Shield Therapeutics INC | $17.67 | 2023 | Accrufer |
| Alexion Pharmaceuticals, INC. | $17.51 | 2022 | |
| Edwards Lifesciences Corporation | $15.97 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.31 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.52 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.17 | 2024 | Voquezna |
| Valinor Pharma, LLC | $13.63 | 2023 | Movantik |
| Bayer Healthcare Pharmaceuticals INC. | $12.32 | 2022 | |
| Convatec INC. | $11.95 | 2022 | |
| Amarin Pharma, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Saripalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.